NYMC Faculty Publications
Additional Author Affiliation
New York Medical College
Author ORCID Identifier
http://orcid.org/0000-0001-7916-6625
Journal Title
British Journal of Haematology
First Page
887
Last Page
898
Document Type
Article
Publication Date
6-1-2015
Department
Public Health
Abstract
Pulmonary hypertension (PH) commonly develops in thalassaemia syndromes, but is poorly characterized. The goal of this study was to provide a comprehensive description of the cardiopulmonary and biological profile of patients with thalassaemia at risk for PH. A case-control study of thalassaemia patients at high versus low PH-risk was performed. A single cross-sectional measurement for variables reflecting cardiopulmonary status and biological pathophysiology were obtained, including Doppler-echocardiography, 6-min-walk-test, Borg Dyspnoea Score, New York Heart Association functional class, cardiac magnetic resonance imaging (MRI), chest-computerized tomography, pulmonary function testing and laboratory analyses targeting mechanisms of coagulation, inflammation, haemolysis, adhesion and the arginine-nitric oxide pathway. Twenty-seven thalassaemia patients were evaluated, 14 with an elevated tricuspid-regurgitant-jet-velocity (TRV) ≥ 2·5 m/s. Patients with increased TRV had a higher frequency of splenectomy, and significantly larger right atrial size, left atrial volume and left septal-wall thickness on echocardiography and/or MRI, with elevated biomarkers of abnormal coagulation, lactate dehydrogenase (LDH) levels and arginase concentration, and lower arginine-bioavailability compared to low-risk patients. Arginase concentration correlated significantly to several echocardiography/MRI parameters of cardiovascular function in addition to global-arginine-bioavailability and biomarkers of haemolytic rate, including LDH, haemoglobin and bilirubin. Thalassaemia patients with a TRV ≥ 2·5 m/s have additional echocardiography and cardiac-MRI parameters suggestive of right and left-sided cardiac dysfunction. In addition, low arginine bioavailability may contribute to cardiopulmonary dysfunction in β-thalassaemia.
Recommended Citation
Morris, C., Kim, H., Klings, E., Wood, J., Porter, J. B., Trachtenberg, F., Kuypers, F., Vichinsky, E., & Kuypers, F. (2015). Dysregulated Arginine Metabolism and Cardiopulmonary Dysfunction in Patients with Thalassaemia. British Journal of Haematology, 169 (6), 887-898. https://doi.org/10.1111/bjh.13452
Publisher's Statement
This is the peer reviewed version of the following article: Morris, C. R., Kim, H. Y., Klings, E. S., Wood, J., Porter, J. B., Trachtenberg, F., … Thalassemia Clinical Research Network (2015). Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British journal of haematology, 169(6), 887–898. doi:10.1111/bjh.13452, which has been published in final form at https://doi.org/10.1111/bjh.13452. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Comments
At the time of publication, Dr. Kim was affiliated with New England Research Institutes in Watertown, MA. Please see the work itself for the complete list of authors.